Pomalidomide

Generic Name
Pomalidomide
Brand Names
Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C13H11N3O4
CAS Number
19171-19-8
Unique Ingredient Identifier
D2UX06XLB5
Background

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Indication

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...

Associated Conditions
Kaposi's Sarcoma, Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

First Posted Date
2021-05-20
Last Posted Date
2023-03-06
Lead Sponsor
AbbVie
Target Recruit Count
8
Registration Number
NCT04895410
Locations
🇺🇸

Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States

🇺🇸

Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States

🇺🇸

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States

and more 29 locations

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2021-05-19
Last Posted Date
2024-11-01
Lead Sponsor
Gilead Sciences
Target Recruit Count
35
Registration Number
NCT04892446
Locations
🇺🇸

US Oncology, Inc., IRB, Fairfax, Virginia, United States

🇺🇸

US San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Stanford Cancer Institute, Palo Alto, California, United States

and more 19 locations

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-05-12
Last Posted Date
2024-07-03
Lead Sponsor
University of Washington
Target Recruit Count
37
Registration Number
NCT04883242
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-04-20
Last Posted Date
2024-12-05
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
5
Registration Number
NCT04850599
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

First Posted Date
2021-04-13
Last Posted Date
2023-10-25
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
4
Registration Number
NCT04843579
Locations
🇺🇸

Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States

🇺🇸

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2021-04-08
Last Posted Date
2024-02-07
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
53
Registration Number
NCT04835129
Locations
🇺🇸

The University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

First Posted Date
2021-03-17
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
78
Registration Number
NCT04802161
Locations
🇺🇸

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States

🇺🇸

University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 8 locations

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

First Posted Date
2021-02-21
Last Posted Date
2024-01-17
Lead Sponsor
Mayo Clinic
Target Recruit Count
81
Registration Number
NCT04764942
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-02-21
Last Posted Date
2021-02-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
56
Registration Number
NCT04762745
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted Date
2021-01-25
Last Posted Date
2024-10-09
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
140
Registration Number
NCT04722146
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 24 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy